FDA Execs Prefer Novel Switch Model Sans Intervention
This article was originally published in The Pink Sheet Daily
Executive Summary
Leaders at FDA’s drug center appear more closely aligned with the OTC industry than with medical professionals’ groups on consumer access to innovative switches. CDER Director Woodcock says the clinical community has resisted switches – and been proven wrong – before.